+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Tumor Ablation Market Report and Forecast 2024-2032

  • PDF Icon


  • 140 Pages
  • April 2024
  • Region: Global
  • Expert Market Research
  • ID: 5960370
The global tumor ablation market size was valued at USD 1.9 billion in 2023. It is expected to grow at a CAGR of 14.2% during the forecast period of 2024-2032, driven by the rising preference for minimally invasive surgeries over traditional open surgeries across the globe. The market is experiencing robust growth and is expected to reach USD 6.3 billion by 2032.

Global Tumor Ablation Market Analysis

The global tumor ablation market is experiencing robust growth, driven by the increasing prevalence of cancer worldwide and the rising demand for minimally invasive treatment options. Tumor ablation refers to a set of techniques used to destroy cancer cells in the body without the need for traditional surgery. These methods, including radiofrequency, microwave, cryoablation, and laser ablation, offer patients reduced recovery times, lower risk of complications, and the potential for targeted treatment of tumors.

Current Market Dynamics

The expansion of the tumor ablation market is propelled by technological advancements that enhance the efficacy and safety of ablation procedures. Innovations in imaging technologies, such as ultrasound and MRI, have improved the precision of tumor targeting, increasing the success rates of ablation therapies. Additionally, the growing adoption of personalized medicine approaches, which aim to tailor treatment to individual patient characteristics, is fostering a greater reliance on tumor ablation as a key therapeutic option.

Global Tumor Ablation Market Drivers

  • Rising Cancer Incidence: The global increase in cancer cases is the primary driver of the tumor ablation market, creating a pressing need for effective and efficient treatment modalities.
  • Technological Advancements: Continuous improvements in ablation equipment and techniques, along with better imaging and monitoring technologies, are enhancing treatment outcomes.
  • Preference for Minimally Invasive Procedures: Patients and healthcare providers are increasingly favoring minimally invasive treatments due to their advantages over open surgeries, including reduced hospital stays and lower risk of infections.
  • Increasing Healthcare Expenditure: Higher healthcare spending across both developed and emerging markets is enabling greater access to advanced cancer treatments, including tumor ablation.


Despite its growth, the tumor ablation market faces several challenges, including:

  • High Treatment Costs: The expense associated with advanced ablation technologies can limit access for patients in lower-income regions.
  • Lack of Awareness: In some areas, there is a lack of awareness among patients and healthcare providers about the benefits and availability of tumor ablation treatments.
  • Regulatory Hurdles: The approval process for new ablation devices and technologies can be lengthy and complex, potentially delaying market entry.

Global Tumor Ablation Market Outlook

The future of the tumor ablation market looks promising, with ongoing research focused on developing more precise and less invasive ablation methods. There is also a trend toward integrating ablation therapies with other cancer treatments, such as chemotherapy and immunotherapy, to enhance overall efficacy. As the global burden of cancer continues to rise, the demand for advanced tumor ablation techniques is expected to grow, offering significant opportunities for market expansion.

The global tumor ablation market is set for continued advancement and growth, driven by the rising incidence of cancer, technological innovations, and the increasing preference for minimally invasive treatments. Overcoming challenges related to cost, awareness, and regulatory approval will be key to maximizing the potential of tumor ablation therapies. As the market evolves, it will play a crucial role in transforming cancer treatment, improving patient outcomes, and reducing the impact of cancer on individuals and healthcare systems worldwide.

Global Tumor Ablation Market Trends

The global tumor ablation market is experiencing significant growth due to advancements in technology, an increase in the prevalence of cancer, and the rising demand for minimally invasive procedures. Here are some key trends shaping the market:
  • Technological Advancements
Innovations in ablation technology, such as microwave ablation, irreversible electroporation, and high-intensity focused ultrasound (HIFU), are improving the efficacy and safety of tumor ablation procedures. These advancements are expected to drive market growth by offering better outcomes for patients.
  • Increasing Prevalence of Cancer
The rising incidence of cancer worldwide is a major driver for the tumor ablation market. As more people are diagnosed with cancer, the demand for effective and minimally invasive treatment options like tumor ablation is increasing.
  • Shift Towards Minimally Invasive Procedures
There is a growing preference for minimally invasive surgeries over traditional open surgeries due to benefits such as shorter hospital stays, less post-operative pain, and quicker recovery times. This trend is boosting the adoption of tumor ablation techniques.
  • Expanding Applications
Initially used primarily for liver cancer, tumor ablation is now being applied to a wider range of cancers, including lung, kidney, bone, and prostate cancer. This expansion in applications is contributing to market growth.
  • Personalized Medicine
The integration of personalized medicine approaches in cancer treatment is leading to the development of targeted ablation therapies. These therapies are designed based on the genetic and molecular profiles of individual tumors, improving treatment efficacy.
  • Collaborations and Partnerships
Key players in the market are increasingly engaging in collaborations, partnerships, and acquisitions to expand their product portfolios and geographic reach. This trend is expected to continue, fostering innovation and market expansion.
  • Regulatory Approvals
The approval of new ablation devices by regulatory authorities like the FDA and EMA is facilitating the introduction of innovative products into the market, further driving growth.
  • Emerging Markets
Developing countries in regions such as Asia-Pacific and Latin America are witnessing rapid growth in the tumor ablation market due to increasing healthcare expenditure, growing awareness about cancer treatment options, and improving healthcare infrastructure.
  • Reimbursement Policies
Favorable reimbursement policies for tumor ablation procedures in developed countries are encouraging the adoption of these treatments, thereby supporting market growth.
  • Challenges and Constraints
Despite the positive outlook, the market faces challenges such as high treatment costs, lack of skilled professionals, and concerns about the long-term efficacy and safety of ablation techniques.

Global Tumor Ablation Market Segmentation

Market Breakup by Technology

  • Radiofrequency Ablation
  • Microwave Ablation
  • Cryoablation
  • HIFU
  • Others
The global tumor ablation market is segmented by technology into radiofrequency ablation, microwave ablation, cryoablation, high-intensity focused ultrasound (HIFU), and others. Radiofrequency ablation is a leading segment due to its efficacy and minimal invasiveness. Microwave ablation is gaining traction for its precise and rapid treatment capabilities. Cryoablation is favored for its applicability in treating various cancers with minimal side effects. HIFU is emerging as a promising non-invasive technique, especially in treating prostate and liver tumors. These technologies are driving market growth by offering effective, less invasive alternatives to traditional surgery, with future advancements expected to further enhance their adoption in the forecast period.

Market Breakup by Type

  • Surgical Ablation
  • Percutaneous Ablation
  • Laparoscopic Ablation
The global tumor ablation market is categorized by type into surgical ablation, percutaneous ablation, and laparoscopic ablation. Surgical ablation is a traditional approach offering direct access to tumors, but with higher invasiveness. Percutaneous ablation, a minimally invasive technique, is gaining popularity for its ability to target tumors accurately with less recovery time. Laparoscopic ablation, combining minimally invasive surgery with advanced imaging, is preferred for its precision and reduced postoperative complications. These types are poised to drive market growth by offering diverse options tailored to patient needs and tumor characteristics, with percutaneous and laparoscopic ablation expected to see significant growth due to their minimally invasive nature.

Market Breakup by Application

  • Kidney Cancer
  • Liver Cancer
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Bone Cancer
The global tumor ablation market is segmented by application into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and bone cancer. Kidney and liver cancers are leading segments due to the high incidence rates and effectiveness of ablation techniques in treating these tumors. Breast and lung cancers are also significant segments, with ablation being increasingly used as a treatment option. Prostate and bone cancers are emerging segments, with growing adoption of minimally invasive ablation methods. The market is poised for growth across all applications, driven by the rising prevalence of cancer and the demand for less invasive, targeted treatment options.

Market Breakup by End User

  • Hospitals
  • Oncology Centers
  • Others
The global tumor ablation market is segmented by end-user into hospitals, oncology centers, and others. Hospitals are the largest segment, due to their comprehensive healthcare services and the availability of advanced ablation technologies. Oncology centers are specialized facilities focused on cancer treatment, including ablation, and are experiencing significant growth due to their expertise and state-of-the-art equipment. The "others" category includes ambulatory surgical centers and clinics, which are becoming increasingly popular for their convenience and cost-effectiveness. The market is poised for growth across all end-user segments, with hospitals and oncology centers leading the way due to their pivotal role in cancer treatment.

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
The global tumor ablation market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America leads the market due to its advanced healthcare infrastructure, high healthcare expenditure, and the presence of key market players. Europe follows closely, with a strong focus on cancer research and healthcare innovation. The Asia Pacific region is expected to witness the fastest growth, driven by increasing cancer prevalence, improving healthcare facilities, and rising investments in healthcare. Latin America and the Middle East and Africa are emerging markets, with growing awareness and adoption of tumor ablation techniques.

Global Tumor Ablation Market Competitive Landscape

The competitive landscape of the global tumor ablation market is characterized by the presence of leading players such as Medtronic PLC, Boston Scientific Corporation, Johnson & Johnson, AngioDynamics, EDP TMS, Mermaid Medical, CONMED Corporation, Sonablate Corporation, Integra Life Science Holding Corporation, Olympus Corporation, and Smith & Nephew PLC. These companies are at the forefront of innovation, offering a range of ablation technologies and devices to cater to diverse needs in cancer treatment. They are engaged in strategic collaborations, acquisitions, and research and development activities to enhance their product portfolios and expand their market presence. The competition is intense, with companies constantly striving to develop more effective and minimally invasive solutions to gain a competitive edge in the market.

Key Questions Answered in This Report

  • What is the current and future performance of the global tumor ablation market?
  • What factors are driving the growth of the tumor ablation market?
  • What are the drivers and challenges of the tumor ablation market?
  • How is the preference for minimally invasive surgeries impacting the tumor ablation market?
  • How are collaborations and acquisitions shaping the tumor ablation market?
  • How are cryoablation and HIFU technologies influencing the tumor ablation market?
  • How are laparoscopic and percutaneous ablation methods driving tumor ablation market growth?
  • How is the tumor ablation market segmented by application, and what drives its growth?
  • Who are the key players in the global tumor ablation market, and what strategies are they employing?

Key Benefits for Stakeholders

  • The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global tumor ablation market from 2017-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the global tumor ablation market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global tumor ablation industry and its attractiveness.
  • The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Tumor Ablation Market Overview
3.1 Global Tumor Ablation Market Historical Value (2017-2023)
3.2 Global Tumor Ablation Market Forecast Value (2024-2032)
4 Global Tumor Ablation Market Landscape*
4.1 Global Tumor Ablation: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Tumor Ablation: Product Landscape
4.2.1 Analysis by Technology
4.2.2 Analysis by Type
4.2.3 Analysis by Application
5 Global Tumor Ablation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Tumor Ablation Market Segmentation (2017-2032)
6.1 Global Tumor Ablation Market (2017-2032) by Technology
6.1.1 Market Overview
6.1.2 Radiofrequency Ablation
6.1.3 Microwave Ablation
6.1.4 Cryoablation
6.1.5 HIFU
6.1.6 Others
6.2 Global Tumor Ablation Market (2017-2032) by Type
6.2.1 Market Overview
6.2.2 Surgical Ablation
6.2.3 Percutaneous Ablation
6.2.4 Laparoscopic Ablation
6.3 Global Tumor Ablation Market (2017-2032) by Application
6.3.1 Market Overview
6.3.2 Kidney Cancer
6.3.3 Liver Cancer
6.3.4 Breast Cancer
6.3.5 Lung Cancer
6.3.6 Prostate Cancer
6.3.7 Bone Cancer
6.4 Global Tumor Ablation Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Oncology Centers
6.4.4 Others
6.5 Global Tumor Ablation Market (2017-2032) by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Tumor Ablation Market (2017-2032)
7.1 North America Tumor Ablation Market (2017-2032) by Technology
7.1.1 Market Overview
7.1.2 Radiofrequency Ablation
7.1.3 Microwave Ablation
7.1.4 Cryoablation
7.1.5 HIFU
7.1.6 Others
7.2 North America Tumor Ablation Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Kidney Cancer
7.2.3 Liver Cancer
7.2.4 Breast Cancer
7.2.5 Lung Cancer
7.2.6 Prostate Cancer
7.2.7 Bone Cancer
7.3 North America Tumor Ablation Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Tumor Ablation Market (2017-2032)
8.1 Europe Tumor Ablation Market (2017-2032) by Technology
8.1.1 Market Overview
8.1.2 Radiofrequency Ablation
8.1.3 Microwave Ablation
8.1.4 Cryoablation
8.1.5 HIFU
8.1.6 Others
8.2 Europe Tumor Ablation Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Kidney Cancer
8.2.3 Liver Cancer
8.2.4 Breast Cancer
8.2.5 Lung Cancer
8.2.6 Prostate Cancer
8.2.7 Bone Cancer
8.3 Europe Tumor Ablation Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Tumor Ablation Market (2017-2032)
9.1 Asia Pacific Tumor Ablation Market (2017-2032) by Technology
9.1.1 Market Overview
9.1.2 Radiofrequency Ablation
9.1.3 Microwave Ablation
9.1.4 Cryoablation
9.1.5 HIFU
9.1.6 Others
9.2 Asia Pacific Tumor Ablation Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Kidney Cancer
9.2.3 Liver Cancer
9.2.4 Breast Cancer
9.2.5 Lung Cancer
9.2.6 Prostate Cancer
9.2.7 Bone Cancer
9.3 Asia Pacific Tumor Ablation Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Tumor Ablation Market (2017-2032)
10.1 Latin America Tumor Ablation Market (2017-2032) by Technology
10.1.1 Market Overview
10.1.2 Radiofrequency Ablation
10.1.3 Microwave Ablation
10.1.4 Cryoablation
10.1.5 HIFU
10.1.6 Others
10.2 Latin America Tumor Ablation Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Kidney Cancer
10.2.3 Liver Cancer
10.2.4 Breast Cancer
10.2.5 Lung Cancer
10.2.6 Prostate Cancer
10.2.7 Bone Cancer
10.3 Latin America Tumor Ablation Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Tumor Ablation Market (2017-2032)
11.1 Middle East and Africa Tumor Ablation Market (2017-2032) by Technology
11.1.1 Market Overview
11.1.2 Radiofrequency Ablation
11.1.3 Microwave Ablation
11.1.4 Cryoablation
11.1.5 HIFU
11.1.6 Others
11.2 Middle East and Africa Tumor Ablation Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Kidney Cancer
11.2.3 Liver Cancer
11.2.4 Breast Cancer
11.2.5 Lung Cancer
11.2.6 Prostate Cancer
11.2.7 Bone Cancer
11.3 Middle East and Africa Tumor Ablation Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Medtronic PLC
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Boston Scientific Corporation
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Johnson & Johnson
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 AngioDynamics
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 EDP TMS
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Mermaid Medical
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 CONMED Corporation
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Sonablate Corporation
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Integra Life Science Holding Corporation
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Olympus Corporation
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Smith & Nephew PLC
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
List not exhaustive
18 Global Tumor Ablation Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The research team strives to make this section as comprehensive as possible.

Companies Mentioned

  • Medtronic PLC
  • Boston Scientific Corporation
  • Johnson & Johnson
  • AngioDynamics
  • Mermaid Medical
  • CONMED Corporation
  • Sonablate Corporation
  • Integra Life Science Holding Corporation
  • Olympus Corporation
  • Smith & Nephew PLC